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Background: Studies have shown that omega-3 fatty acids reduce the concentrations of
eicosanoids, cytokines, chemokines, C-reactive protein (CRP) and other inﬂammatory medi-
ators.
Objective: To investigate the effects of omega-3 fatty acids on circulating levels of inﬂam-
matory mediators and biochemical markers in women with systemic lupus erythematosus
(SLE).
Methods: Experimental clinical study (clinical trial: NCT02524795); 49 women with SLE
(ACR1982/1997) were randomized: 22 to the omega-3 group (daily intake of 1080 mg
EPA  + 200 mg DHA, for 12 weeks) and 27 to the control group. The inﬂammatory medi-
ators and biochemical markers at T0 and T1 in omega-3 group were compared using
Wilcoxon  test. U-Mann–Whitney test was used to compare variations of measured variables
[V  = pre-treatment (T0) − post-treatment (T1) concentrations] between groups. p < 0.05 was
considered signiﬁcant.
Results: The median (interquartile range – IQR) of age was 37 (29–48) years old, of disease
duration was 7 (4–13) years, and of SLEDAI-2K was 1 (0–2). The median (IQR) of variation in
CRP  levels between the two groups showed a decrease in omega-3 group while there was anoup (p = 0.008). The serum concentrations of IL-6 and IL-10, leptin andincrease in control grPlease cite this article in press as: Curado Borges M, et al. Omega-3 fatty acids, inﬂammatory status and biochemical markers of patients with
systemic lupus erythematosus: a pilot study. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.09.014
adiponectin did not change after a 12 week treatment.
Conclusions: Supplementation with omega-3 had no impact on serum concentrations of IL-6,
IL-10,  leptin and adiponectin in women with SLE and low disease activity. There was a
 Study conducted at Unidade de Reumatologia, Hospital das Clínicas; Faculdade de Medicina, Departamentos de Sistema Locomotor,
irurgia e Medicina Interna, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
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signiﬁcant decrease of CRP levels as well as evidence that omega-3 may impact total and
LDL-cholesterol.
©  2016 Published by Elsevier Editora Ltda. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Ácidos  graxos  ômega-3,  estado  inﬂamatório  e  marcadores  bioquímicos
de  pacientes  com  lúpus  eritematoso  sistêmico:  estudo  piloto
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Introduc¸ão: Estudos têm mostrado que os ácidos graxos ômega-3 reduzem as concentrac¸ões
séricas de eicosanoides, citocinas, quimiocinas, proteína C-reativa (PCR) e outros medi-
adores  inﬂamatórios.
Objetivo: Investigar os efeitos dos ácidos graxos ômega-3 sobre os níveis circulantes de
mediadores inﬂamatórios e marcadores bioquímicos em mulheres com lúpus eritematoso
sistêmico (LES).
Métodos: Ensaio clínico randomizado (ensaio clínico: NCT02524795); foram randomizadas
49  mulheres com LES (ACR1982/1997): 22 para o grupo ômega-3 (dose diária de 1.080 mg
de  EPA + 200 mg de DHA durante 12 semanas) e 27 para o grupo controle. Os mediadores
inﬂamatórios e marcadores bioquímicos em T0 e T1 no grupo ômega-3 foram comparados
pelo teste de Wilcoxon. O teste U de Mann–Whitney foi usado para comparar variac¸ões
das  variáveis mensuradas [V = concentrac¸ões pré-tratamento (T0) − concentrac¸ões pós-
tratamento (T1)] entre os grupos. Um p < 0,05 foi considerado signiﬁcativo.
Resultados: A mediana (intervalo interquartil – IIQ) da idade foi de 37 anos (29 - 48), a durac¸ão
da  doenc¸a foi de sete anos (4 - 13) anos e o Systemic Lupus Disease Activity Index (SLEDAI-2K) foi
de  1 (0 - 2). A mediana (IIQ) da variac¸ão nos níveis de PCR entre os dois grupos mostrou um
decréscimo no grupo ômega-3, enquanto houve um aumento no grupo controle (p = 0,008).
As  concentrac¸ões séricas de IL-6 e IL-10, leptina e adiponectina não se alteraram após um
tratamento de 12 semanas.
Conclusões: A suplementac¸ão de ômega-3 não teve impacto sobre as concentrac¸ões séricas de
IL-6,  IL-10, leptina e adiponectina em mulheres com LES e baixa atividade da doenc¸a. Houve
uma diminuic¸ão signiﬁcativa nos níveis de PCR, bem como evidências de que o ômega-3
pode  impactar sobre o colesterol total e LDL.
© 2016 Publicado por Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma
c¸a  Clicen
Introduction
Omega-3 fatty acids have been considered antiinﬂamma-
tory lipids based on epidemiological studies of Greenland
Eskimos, whose diet is rich in polyunsaturated fatty acids
from ﬁsh. The prevalence of diseases with an inﬂam-
matory component such as acute myocardial infarction,
diabetes mellitus, multiple sclerosis, asthma and thyrotoxico-
sis, was lower in the Eskimos compared to Western countries
populations.1
Fatty acids of the omega-3 family [mainly the -linolenic
acid, eicosapentaenoic (EPA) and docosahexaenoic (DHA)],
as well as those of the omega-6 family [represented mainly
by linoleic acid and arachidonic acid (AA)] are essential for
the synthesis of eicosanoids, prostaglandins, leukotrienes,
thromboxanes and other oxidative factors, major mediators
and regulators of inﬂammation.2,3 Studies have shown that
omega-3 fatty acids control inﬂammation by reducing C-Please cite this article in press as: Curado Borges M, et al. Omega-3 fatty a
systemic lupus erythematosus: a pilot study. Rev Bras Reumatol. 2016. htt
reactive protein (CRP), eicosanoid proinﬂammatory cytokines,
chemokines and other inﬂammatory mediators.4–7 Further-
more,  they present beneﬁcial effects in the prevention andC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
control of cardiovascular diseases, dyslipidemia and diabetes
mellitus.8–13
Systemic lupus erythematosus (SLE) is an inﬂammatory
autoimmune disease characterized by loss of cellular immune
regulation balance and increased levels of circulating inﬂam-
matory mediators.14 Thus, omega-3 supplementation could
represent additional therapy for individuals with SLE. How-
ever, little is known on the role of these fatty acids in patients
with SLE, including the effects on inﬂammatory cytokine con-
centrations and on disease activity.
The aim of this study was to investigate the effects of
omega-3 fatty acids on circulating levels of inﬂammatory
mediators and biochemical markers in women with SLE.
Patients  and  methods
This is a clinical trial of the use of omega-3-polyunsaturatedcids, inﬂammatory status and biochemical markers of patients with
p://dx.doi.org/10.1016/j.rbre.2016.09.014
fatty acids in SLE patients followed at the Rheumatology Unit
of Hospital das Clínicas, Universidade Federal de Minas Gerais,
UFMG (clinical trial: NCT02524795). The Research Ethics
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ommittee of UFMG approved the study. All patients provided
 written informed consent.
tudy  participants
emale patients who met  the revised American Col-
ege of Rheumatology (ACR) classiﬁcation criteria for SLE
1982/1997),15 aged over 18 years old and below 60 years old,
aking stable doses of medications for SLE treatment in thePlease cite this article in press as: Curado Borges M, et al. Omega-3 fatty a
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ast three months were included. Exclusion criteria were the
ollowing: pregnancy, disease duration of less than one year,
llergy to ﬁsh, ﬁsh oil or any omega-3 product, omega-3 use
ithin the previous six months and diagnosis of diabetes
Patients scre
assessed for el
(n=153)
Patients rando
(n=66)
Allocated to omega-3 group
(n=33 )
Completed study (n=22)
Discontinued from study (n=11)
2 adverse events
2 disease activation
1 change in SLE medication dosage
1 lack of adherence to supplementation
5 loss of serum samples
Not included (n=87)
42 diabetes mellitus
30 presence of infection
15 active nephritis
Fig. 1 – Study 6;x  x x(x x):xxx–xxx 3
mellitus, liver disease, active nephritis, chronic renal failure,
any type of infection at enrollment and/or throughout the
study.
A total of 153 patients were screened for the trial and
66 patients were included, with 33 randomized to each arm.
Twenty-two women in the study group and 27 in the control
group completed the whole protocol and had both their ﬁrst
and 12-week visit assessments (Fig. 1).cids, inﬂammatory status and biochemical markers of patients with
p://dx.doi.org/10.1016/j.rbre.2016.09.014
Study  design
A 12 week clinical trial of omega-3 fatty acids supplemen-
tation was conducted. Participants were seen at baseline (T0)
ened
igibility
mized
Allocated to control group
(n=33)
Completed study (n=27)
Discontinued from study  (n=6)
2 disease activation
1 change in SLE medication dosage
3 loss of serum samples
 design.
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Table 1 – Baseline (T0) characteristics of each group.
Total
n  = 49
Omega-3 group
n = 22
Control group
n = 27
pc
Mucocutaneous disordersa 20 (40.8) 9 (40.9) 11 (40.7) 0.829
Arthritisa 3 (6.1) 1 (4.5) 2 (7.4) 0.724
Hematological disordersa 27 (55.1) 13 (59.1) 14 (51.9) 0.340
Lymphopeniaa 26 (53.1) 13 (59.1) 13 (48.1) 0.233
Leukopeniaa 10 (20.4) 3 (13.6) 7 (25.9) 0.390
Thrombocytopeniaa 1 (2.0) 0  1 (3.7) 0.390
Nephritisa 11 (22.4) 5  (22.7) 6  (22.2) 0.861
Low C3a 9 (18.0) 2  (9.1) 7 (25.0) 0.146
Low C4a 10 (20.4) 3 (14.3) 3 (11.1) 0.102
Positive double strand antiDNAa 6 (12.5) 3 (14.3) 3 (11.1) 0.741
Current steroid dose (mg)b 5.0 (2.5–10.0) 5.0 (0.6–10.0) 5.0 (3.5–8.1) 0.745
Cumulative steroid dose (g)b 20.0 (12.2–37.8) 22.0 (12.7–56.7) 19.1 (12.1–30.5) 0.178
SLEDAI-2Kb 1 (0–2) 0 (0–2) 2 (0–4) 0.072
BMI (kg/m2)b 28.4 (25.7–30.9) 29.0 (25.7–30.7) 28.1 (25.2–31.4) 0.805
Body fat %b 36.9 (33.7–41.1) 37.7 (33.2–41.9) 36.0 (33.1–38.8) 0.512
Obesitya 17 (34.7) 8 (36.4) 9 (33.3) 0.689
Current immunosuppressor usea 33 (64.7) 13 (59.1) 20 (69.0) 0.465
BMI, body mass index.
a N (%).
b Median (interquartil range).
c Pearson’s Chi-square, Fisher’s exact or U-Mann–Whitney test.
and at week 12 (T1) for clinical, laboratory and nutritional
assessment. Participants were also contacted by telephone at
week 6 to check on compliance and any adverse events. The
patients were randomized into one of two groups in a 1:1 ratio.
Patients in the study group received, throughout 12 weeks, two
tablets taken orally once daily of omega-3 fatty acids (540 mg  of
EPA and 100 mg  of DHA; Hiomega-3 supplement of Naturalis®
company - registered in the National Health Department num-
ber 4.1480.0006.001-4). Patients in the control group did not
receive the nutrient nor any kind of placebo. All participants
were instructed not to take omega-3 rich foods during the
study period. The researcher (FMMS) who  did clinical assess-
ment and the inﬂammatory and biochemical data assessment
was blind to randomization and intervention. Any adverse
events observed during the study were recorded and managed
according to local clinical practice.
Variables measured at each visit included: disease activ-
ity index, using the Systemic Lupus Disease Activity Index
(SLEDAI-2k)16; damage index (Systemic Lupus International
Collaboration Clinics/American College of Rheumatology
damage index - SLICC/ACR)17; fasting lipid and glucose pro-
ﬁle; standard laboratory tests to assess SLE (red and white
blood count, platelet count, creatinine, urinalysis, urine pro-
tein/creatinine ratio, anti-dsDNA, anticardiolipin, C3 and C4
levels); cytokines (IL-6, IL-10), adipokines (leptin, adiponectin)
C-reactive protein (CRP), nutritional assessment, and medica-
tions being used.
Nutritional status was assessed by body mass index
(BMI) and patients were classiﬁed as malnourished (BMI ≤
18.5 kg/m2), normal weight (BMI = 18.6–24.9 kg/m2), over-
weight (BMI = 25–29.9 kg/m2) and obese (BMI ≥ 30 kg/m2).18
Body composition assessment was performed by usingPlease cite this article in press as: Curado Borges M, et al. Omega-3 fatty a
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bioimpedance (RJL Quantum X®) and patients were classiﬁed
in accordance to Gallagher et al. 19 as normal or above the
recommended percentage body fat according to sex and age.The IL-6 and IL-10 levels were assessed by ultrasen-
sitive ﬂow cytometry (Cytometric Bead Array), leptin and
adiponectin levels by ELISA.
Outcome  variables
The primary outcomes were median (interquartile range – IQR)
variations [V = pre-treatment (T0) − post-treatment (T1) con-
centrations], between groups, of serum cytokines, adipokines,
C-reactive protein and biochemical markers (glucose and
lipids) after a 12 week treatment.
Statistical  analysis
The Statistical Package of Social Sciences Software (SPSS) ver-
sion 19.0 (SPSS Inc., Chicago, IL, USA) was used. Comparison
of groups at baseline (with versus without omega-3, with ver-
sus without excess weight and with adequate versus above
recommended percentage body fat) were performed by non-
parametric U-Mann–Whitney test for continuous variables,
and Pearson’s chi-square or Fisher’s exact test for categorical
variables. The median (IQR) of inﬂammatory and biochemical
markers at T0 and T1 in omega-3 and in control group were
compared using nonparametric Wilcoxon test.
To investigate the effect of omega-3 on inﬂammatory
mediators and biochemical markers the variations of labora-
tory variables [V = pre-treatment (T0) − post-treatment (T1)
concentrations] between omega-3 and control groups were
analyzed using U-Mann–Whitney test. All analyses were con-
sidered signiﬁcant at a level of 2-sided 5% (p < 0.05).cids, inﬂammatory status and biochemical markers of patients with
p://dx.doi.org/10.1016/j.rbre.2016.09.014
Results
Seventeen randomized patients, out of 66, did not complete
the trial (Fig. 1). Two patients interrupted supplementation due
ARTICLE IN PRESSRBRE-332; No. of Pages 9
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Table 2 – Serum concentrations of cytokines, adipokines and biochemical markers of SLE patients at baseline (T0) by
treatment groups.
Omega-3 group
n = 22
Median (IQR)
Control group
n = 27
Median (IQR)
pe
IL-6 (pg/mL) 0.57 (0.40–2.90)a 1.09 (0.52–1.98)b 0.692
IL-10 (pg/mL) 19.05 (9.88–40.87)c 21.41 (6.72–51.64)d 0.699
Leptin (ng/mL) 80.03 (63.21–129.40) 58.12 (36.65–109.20) 0.067
Adiponectin (g/mL) 42.30 (24.88–58.01) 40.08 (27.69–59.47) 0.817
Glucose (mg/dL) 77.5 (75.2–82.8) 78.0 (71.0–86.0) 0.958
Cholesterol (mg/dL) 168.0 (151.0–194.0) 182.0 (155.5–192.2) 0.899
LDL-c (mg/dL) 95.0 (80.0–116.0) 100.0 (84.5–111.8) 0.926
HDL-c (mg/dL) 52.0 (38.0–57.0) 53.0 (37.8–63.2) 0.498
Triglycerides (mg/dL) 88.0 (64.0–124.0) 79.5 (59.5–114.0) 0.311
CRP (mg/dL) 5.0 (4.9–8.1) 6.4 (4.9–11.6) 0.370
IL, interleukin; IQR, interquartile range; CRP, C-reactive protein.
a n = 21.
b n = 26.
c n = 14.
t
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f
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fd n = 21.
e U-Mann–Whitney test.
o adverse events (one patient with diarrhea and the other
eporting ﬁsh aftertaste). Both patients where discontinued
rom the trial. The ﬁnal sample of this pilot study consisted
f 49 patients. Cumulative revised ACR classiﬁcation indi-
ated mucocutaneous manifestations in 86.3% of the patients,
ematological disorders in 80.0%, immunological disorders in
7.6%, arthritis in 66.7%, nephritis in 56.9%, serositis in 16.0%
nd neuropsychiatric disorders in 11.8%.
aseline  analysis
he median (IQR) of age was 37 (29–48) years old, of disease
uration was 7 (4–13) years, of disease activity index was 1
0–2) and of damage index was 0 (0–1).Please cite this article in press as: Curado Borges M, et al. Omega-3 fatty a
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Baseline (T0) clinical, laboratory and disease treatment
haracteristics, disease activity index and nutritional status
f participants per treatment groups were not statistically dif-
erent (Table 1).
Table 3 – Serum concentrations of cytokines, adipokines and bi
Variable Omega 3 group N=22 
T0
Median (IQR)
T1  Median (IQR) 
IL-6 (pg/mL)b 0.57 (0.40–2.90) 1.10 (0.60–2.80) 
IL-10 (pg/mL)b 19.05 (9.88–40.87) 29.90 (9.80–56.30) 
Leptin (ng/mL) 80.03 (63.21–129.40) 93.20 (54.80–153.40) 
Adiponectin (g/mL) 42.30 (24.88–58.01) 44.9 (23.90–57.20) 
Glucose (mg/dL) 77.5 (75.2–82.8) 83.0 (75.0–87.0) 
Cholesterol (mg/dL) 168.0 (151.0–194.0) 188.0 (162.0–214.5) 
LDL-c (mg/dL) 95.0 (80.0–116.0) 115.5 (90.0–129.2) 
HDL-c (mg/dL) 52.0 (38.0–57.0) 53.0 (47.0–67.0) 
Triglycerides (mg/dL) 88.0 (64.0–124.0) 70.0 (57.0–98.5) 
CRP (mg/dL) 5.0 (4.9–8.1) 4.9 (4.9–7.2) 
IL, interleukin; CRP, C-reactive protein.
a Nonparametric paired Wilcoxon.
b IL-6, Omega 3 Group n = 21; control group n = 26; IL-10, Omega 3 Group n Nutritional status of 49 patients, according to BMI, showed
that 13 patients (26.5%) had normal weight, 19 (38.8%) were
overweight and 17 (34.7%) were obese. This distribution was
similar in both groups (p = 0.875). Bioelectrical impedance
analysis indicated that 29 (59.2%) patients had percentage
body fat above recommended: 12 patients (54.5%) in the
omega-3 group and 17 (63.0%) in the control group (p = 0.574).
Serum concentrations of cytokines were similar in normal
weight and excess weight participants (BMI ≥ 25 kg/m2) [IL-
6:1.38 (0.48–3.13) pg/mL versus 0.92 (0.40–1.95) pg/mL; p = 0.429;
IL-10: 19.30 (7.85–53.35) pg/mL versus 21.42 (9.40–51.16) pg/mL;
p = 0.956]. IL-10 levels were similar in both study groups
considering patients with adequate and above recommended
percentage body fat [16.26 (5.51–22.25) pg/mL versus 22.53cids, inﬂammatory status and biochemical markers of patients with
p://dx.doi.org/10.1016/j.rbre.2016.09.014
(9.78–55.79) pg/mL; p = 0.192]. However, serum concentrations
of IL-6 were higher in above recommended percentage
body fat patients, showing a trend toward signiﬁcance [0.48
(0.19–1.04) pg/mL versus 1.22 (0.47–2.38) pg/mL; p = 0.053].
ochemical markers at T0 and T1 in both groups.
Control group N=27
(p = 27) T0
Median (IQR)
T1
Median (IQR)
pa
0.821 1.09 (0.52–1.98) 0.88 (0.33–2.08) 0.946
0.363 21.41 (6.72–51.64) 26.08 (11.38–47.54) 0.332
0.506 58.12 (36.65–109.20) 77.20 (50.00–103.00) 0.416
0.465 40.08 (27.69–59.47) 44.50 (20.00–59.00) 0.462
0.043 78.0 (71.0–86.0) 77.5 (72.2–85.0) 0.354
0.012 182.0 (155.5–192.2) 176.0 (152.0–199.8) 0.067
0.003 100.0 (84.5–111.8) 98.0 (76.0–125.0) 0.019
0.537 53.0 (37.8–63.2) 53.5 (45.5–59.0) 0.857
0.520 79.5 (59.5–114.0) 87.0 (63.2–128.0) 0.657
0.230 6.4 (4.9–11.6) 5.0 (4.9–11.6) 0.009
= 14; control group n = 21.
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Table 4 – Variation (V) of serum cytokines and biochemical markers considering the end (T1) and the beginning (T0) of
the study by treatment groups.
Omega-3 group
Median (IQR)
Control group
Median (IQR)
pe
V IL-6 (pg/mL) 0.12 (−1.19 to 1.45)a −0.05 (−0.57 to 0.58)b 0.915
V IL-10 (pg/mL) 1.32 (−8.94 to 18.80)c 1.04 (−7.17 to 12.19)d 0.920
V Adiponectin (g/mL) 0.6 (−3.2 to 11.8) −3.4 (−6.6 to 5.8) 0.171
V Leptin (ng/mL) 3.4 (−18.2 to 22.6) 0.0 (−16.3 to 28.0) 0.924
V CRP (mg/dL) 0.0 (−1.5 to 0.0) 0.0 (0.0 to 1.5) 0.008
Glucose (mg/dL) −4.0 (−8.0 to 0.0) −1.0 (−8.0 to 4.0) 0.496
Cholesterol (mg/mL) 14.0 (−2.5 to 27.2) 4.5 (−8.5 to 23.8) 0.477
LDL-c (mg/dL) 17.0 (3.0 to 27.0) 10.5 (−2.5 to 20.8) 0.288
HDL-c (mg/dL) 0.0 (−4.5 to 12.5) −0.5 (−7.0 to 5.0) 0.536
Triglycerides (mg/dL) −1.0 (−39.2 to 22.8) −4.5 (−17.8 to 16.8) 0.867
IL, interleukin; IQR, interquartil range; CRP, C-reactive protein.
a n = 21.
b n = 26.
c n = 14.
–4.00
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Fig. 2 – Box-plot of median (range) of C-reactive protein
levels variations (V) between T0 and T1 in treatment andd n = 21.
e U-Mann–Whitney test.
Serum leptin concentrations were higher in excess
weight patients comparing to normal weight ones [84.0
(52.9–12.3) ng/mL versus 47.6 (33.5–73.5) ng/mL; p = 0.033], and
in individuals with above recommended percentage body fat
compared to those with normal percentage body fat [93.8
(56.5–143.6) ng/mL versus 45.8 (33.5–63.6) ng/mL; p = 0.002]. In
contrast, adiponectin levels did not differ between groups
[normal weight: 46.4 (34.6–61.0) g/mL versus excess weight:
42.5 (24.7–58.0) g/mL; p = 0.571; and normal percentage body
fat: 46.4 (35.1–59.4) g/mL versus above recommended percent-
age body fat: 42.9 (24.3–59.6) g/mL; p = 0.365].
Serum levels of IL-6, IL-10 and adipokines, serum fasting
glucose, lipid proﬁle and C-reactive protein at baseline were
similar in omega-3 and control groups (Table 2).
The serum levels of IL-6 and IL-10, leptin and adiponectin
did not change after a 12 week treatment. The concentrations
of fasting blood glucose, total cholesterol and LDL-cholesterol
increased in the omega-3 group, and of LDL-cholesterol
increased in control group, although they remained within
normal limits (Table 3).
Comparison  of  variations  (V)  between  the  two  groups
The median (IQR) variations (V = T1-T0) of cytokines,
adipokines, fasting glucose and lipids concentrations were
similar for the two groups (Table 4). The median (IQR) in CRP
levels variation between the two groups is represented in Fig. 2,
showing a decrease in the omega-3 group while there was an
increase in the control group (p = 0.008).
Discussion
Supplementation with omega-3 (2 g: 1080 mg of EPA and
200 mg  of DHA) for 12 weeks had no impact on serum concen-Please cite this article in press as: Curado Borges M, et al. Omega-3 fatty a
systemic lupus erythematosus: a pilot study. Rev Bras Reumatol. 2016. htt
trations of IL-6 and IL-10 cytokines as well as on adipokines
(leptin and adiponectin) in 49 women with SLE and low dis-
ease activity. Bello et al.20 reported similar results studying
85 SLE patients who presented no reduction in inﬂammatorycontrol groups.
mediators levels (sICAM-1, sVCAM-1 and IL-6) after the use of
higher doses of this fatty acid (3 g of omega-3: 1800 mg  of EPA
and 1200 mg  of DHA) for 12 weeks. In contrast, in healthy sub-
jects, cell culture studies demonstrated that EPA and DHA can
inhibit the production of IL-6, TNF-, IL-1 and IL-1.7,8,21,22 In
a review study, we  found conﬂicting results of the effects of
omega-3 on disease activity, on cytokines and on biochemical
markers levels, due to the many  different methods used.23
This paper indicates an effect of omega-3 on CRP levels
as there was a signiﬁcant variation of serum levels between
groups: there was a decrease in the omega-3 group while
there was an increase in the control group. Studies in healthy
subjects and in patients with chronic inﬂammatory diseasescids, inﬂammatory status and biochemical markers of patients with
p://dx.doi.org/10.1016/j.rbre.2016.09.014
including diabetes, coronary heart disease, ulcerative colitis,
dyslipidemia and rheumatoid arthritis,24–30 have shown that
consumption of omega-3 fatty acids is inversely associated
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ith serum CRP. No information could be found in the litera-
ure about the effects of omega-3 on CRP levels in SLE patients.
The higher serum concentrations of leptin described in
his study in overweight individuals and in those with above
ecommended percentage body fat were also observed by
ther researchers.31–34 Studies evaluating leptin levels in SLE
atients are consistent and indicate higher levels of leptin
ompared to control subjects, even after statistical adjust-
ent for body mass index (BMI), hypertension, hyperlipidemia
nd diabetes.35–38 This ﬁnding suggests that adipose tissue
ould have a signiﬁcant role in SLE inﬂammatory response. In
ontrast to obesity and metabolic diseases, elevated systemic
nd local levels of adiponectin are present in patients with
nﬂammatory and immune-mediated conditions, like SLE.31
ince adiponectin has been found to present both pro and
nti-inﬂammatory activities, controversial ﬁndings have been
bserved on the role of total adiponectin in systemic autoim-
une and inﬂammatory diseases.32
To our knowledge, the analysis of serum leptin and
diponectin levels after omega-3 fatty acid supplementation
n SLE patients is original data of our study. In healthy sub-
ects the results are conﬂicting. Ramel et al.39 found that daily
onsumption of 1.3 g EPA + DHA caused a signiﬁcant reduction
n serum levels of leptin, noting that there was concomitant
eight loss of about 1 kg in these individuals, which could bias
hese results. Itoh et al.40 reported that after treatment with
aily doses of 1.8 g of EPA there was a signiﬁcant increase in
diponectin production in obese rodents and humans. Stud-
es evaluating omega-3 and omega-6 concentrations in red
ell membranes demonstrated positive association between
mega-3 with increased adiponectin and decreased leptin
erum levels, indicating a potential effect of this fatty acid in
ontrolling inﬂammation.41,42 However, other authors showed
o relationship between the consumption of this nutrient and
erum concentrations of those adipokines.43,44
An increase of total serum cholesterol (p = 0.012) and LDL-
 (p = 0.003) in patients receiving omega-3 fatty acid was
een in our study, as well as an increase in serum LDL-
 (p = 0.019) in control group individuals. Nonetheless, the
edian serum concentrations between T1 and T0 remained
ithin the laboratory normal levels. In accordance with our
ndings, Bello et al.20 and Wright et al.44 also described an
ncrease in total cholesterol and in LDL-c in SLE patients who
eceived omega-3. Studies in non SLE subjects with hyper-
riglyceridemia demonstrated increased serum levels of LDL-c
fter supplementation with this fatty acid.45,46 This is a clin-
cally important ﬁnding, since SLE patients are at increased
isk of atherosclerotic cardiovascular disease, which is one
f the leading causes of mortality in these individuals.47–50
nterestingly, in two meta-analysis of population with high
isk of cardiovascular and cerebrovascular diseases there was
o reduction in the frequency of cardiovascular events, coro-
ary and cerebrovascular as well as overall mortality with this
upplementation.51,52
In the present study, the low levels of inﬂammation of
he SLE patients may have contributed to the absence ofPlease cite this article in press as: Curado Borges M, et al. Omega-3 fatty a
systemic lupus erythematosus: a pilot study. Rev Bras Reumatol. 2016. htt
hanges in serum cytokine levels after omega-3 supplemen-
ation. Therefore, it is not possible to rule out a potential
eduction in serum concentrations in patients with moder-
te to high inﬂammatory activity indexes. Longer periods of
1 6;x  x x(x x):xxx–xxx 7
supplementation would yield different results? Larger doses
could be beneﬁcial with no risks to the patients? These ques-
tions can only be answered by long term randomized studies in
which compliance must be controlled by omega-3 cell uptake,
which we did not perform.
In conclusion, in this 12 weeks study in low disease activity
lupus patients, the supplementation with omega-3 fatty acids
was not associated with changes in serum levels of IL-6, IL-10,
leptin and adiponectin, although a signiﬁcant decrease of CRP
concentrations was observed.
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